Patents Examined by Alana Harris Dent
  • Cancer therapy using CLDN6 target-directed antibodies in vivo
    Patent number: 9718886
    Abstract: The invention relates to the treatment and/or prevention of tumor diseases associated with cells expressing CLDN6, in particular cancer and cancer metastasis using antibodies which bind to CLDN6. The present application demonstrates that the binding of antibodies to CLDN6 on the surface of tumor cells is sufficient to inhibit growth of the tumor and to prolong survival and extend the lifespan of tumor patients. Furthermore, binding of antibodies to CLDN6 is efficient in inhibiting growth of CLDN6 positive germ cell tumors such as teratocarcinomas or embryonal carcinomas, in particular germ cell tumors of the testis.
    Type: Grant
    Filed: July 4, 2011
    Date of Patent: August 1, 2017
    Assignees: GANYMED PHARMACEUTICALS AG, JOHANNES GUTENBERG-UNIVERSITAT MAINZ
    Inventors: Ugur Sahin, Ozlem Tureci, Michael Koslowski, Korden Walter, Maria Kreuzberg, Sylvia Luxen
  • SPARC and methods of use thereof
    Patent number: 9671406
    Abstract: The invention provides methods for predicting or determining the response of a mammalian tumor to a chemotherapeutic agent and for treating a mammalian tumor comprising detecting and quantifying the SPARC protein or RNA in a sample isolated from the mammal. The invention further provides kit for predicting the response of a mammalian tumor to a chemotherapeutic agent, comprising a means for the isolation of protein or RNA from the tumor, a SPARC protein or RNA detection and quantification means, control RNAs, and rules for predicting the response of the tumor based on the level of SPARC protein or RNA in tumor.
    Type: Grant
    Filed: January 30, 2015
    Date of Patent: June 6, 2017
    Assignee: Abraxis BioScience, LLC
    Inventors: Vuong Trieu, Neil P. Desai, Patrick Soon-Shiong
  • Beclin 1 phosphorylation
    Patent number: 9671412
    Abstract: Antibodies specific for human Beclin 1 protein phosphorylated Ser234, Ser295, Tyr229, Tyr233 or Try352 are useful in diagnosing diseases such as cancer and impaired autophagy. The invention further relates to human Beclin 1 mutated at Ser234, Ser295, Tyr229, Tyr233 or Try352 with a phospho-silencing residue and uses thereof.
    Type: Grant
    Filed: March 24, 2015
    Date of Patent: June 6, 2017
    Assignee: Board of Regents, The University of Texas System
    Inventors: Beth C. Levine, Richard C. Wang, Yongjie Wei
  • Anti-DCLK1 monoclonal antibodies and methods of production and use thereof
    Patent number: 9663585
    Abstract: Monoclonal antibodies against DCLK1 and conjugates containing these monoclonal antibodies are disclosed. Methods of producing and using these monoclonal antibodies are also disclosed.
    Type: Grant
    Filed: November 6, 2013
    Date of Patent: May 30, 2017
    Assignee: The Board of Regents of the University of Oklahoma
    Inventors: Courtney Houchen, Sripathi M. Sureban, Randal May, Dongfeng Qu, Nathaniel Weygant
  • Carcinoma homing peptide (CHP), its analogs, and methods of using
    Patent number: 9657077
    Abstract: A mini-peptide and its analogs have been found to target gene products to tumors. The peptide, named Carcinoma Homing Peptide (CHP), increased the tumor accumulation of the reporter gene products in five independent tumor models, including one human xenogeneic model. A CHP-IL-12 fusion gene was also developed using CHP and the p40 subunit of IL-12. The product from CHP-IL-12 fusion gene therapy increased accumulation of IL-12 in the tumor environment. In three tumor models, CHP-IL-12 gene therapy inhibited distal tumor growth. In a spontaneous lung metastasis model, inhibition of metastatic tumor growth was improved compared to wild-type IL-12 gene therapy, and in a squamous cell carcinoma model, toxic liver lesions were reduced. The receptor for CHP was identified as vimentin. CHP can be used to improve the efficacy and safety of targeted cancer treatments.
    Type: Grant
    Filed: February 9, 2012
    Date of Patent: May 23, 2017
    Assignees: UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE
    Inventors: Shulin Li, Jeffry Cutrera, Xueqing Xia
  • Human Tim-3 fusion protein capable of blocking Tim-3 signaling pathway
    Patent number: 9644020
    Abstract: The present invention provides a human Tim-3-Ig fusion protein which can block Tim-3 signal pathway, and said Ig fusion protein comprises Tim-3 protein, human Ig fragment, and the linking sequence therebetween. In the present invention, a human Tim-3-Ig gene is obtained by an artificial synthesis process; an expression vector containing the Tim-3-Ig gene is constructed; and the prepared Ig fusion protein is tested in an expression verification experiment, a binding activity experiment, a blocking activity experiment in different cell lines, and in vivo experiments in mice. The human Tim-3-Ig fusion protein prepared in the present invention can be used to treat immunological diseases caused by high expression of Tim-3.
    Type: Grant
    Filed: January 20, 2015
    Date of Patent: May 9, 2017
    Assignee: Institute of Basic Medical Science, the Academy of Military Medical Science of the Chinese PLA
    Inventors: Gencheng Han, Guojiang Chen, Xingwei Jiang, Renxi Wang, He Xiao, Chunmei Hou, Jiahui Yu, Zhi Zhao, Jiannan Feng, Yan Li, Beifen Shen
  • Methods and compositions for diagnosis and treatment of cancer
    Patent number: 9637548
    Abstract: The present invention relates to the identification of nucleic acid and amino acid sequences that are characteristic of colorectal, in particular colonic, and gastric tumor tissues and colorectal, in particular colonic, and gastric tissues, and which represent targets for therapy or diagnosis of such tumor diseases in a subject.
    Type: Grant
    Filed: February 18, 2010
    Date of Patent: May 2, 2017
    Assignees: GANYMED PHARMACEUTICALS AG, JOHANNES GUTENBERG-UNIVERSITAT MAINZ
    Inventors: Ugur Sahin, Özlem Türeci, Michael Koslowski
  • Protection against apoptosis from ionizing radiation
    Patent number: 9585939
    Abstract: The use and screening of modulators of apoptosis is disclosed. The modulators may be, for example, modulator of NF-?B activity. The modulators may be used, for example, in the treatment of NF-?B-mediated diseases, conditions, and injuries.
    Type: Grant
    Filed: February 22, 2016
    Date of Patent: March 7, 2017
    Assignee: THE CLEVELAND CLINIC FOUNDATION
    Inventor: Andrei V. Gudkov
  • Diagnosis and treatment of brain tumor
    Patent number: 9581598
    Abstract: Cellular targets on cancer cells have been identified that can be used with targeted molecular imaging to detect the cancer cells in vivo. Non-invasive methods for detecting cancer cells, such as metastasized cancer cells, are therefore provided. Also provided are compositions and kits for use in the disclosed methods.
    Type: Grant
    Filed: April 25, 2013
    Date of Patent: February 28, 2017
    Assignee: Sanford-Burnham Medical Research Institute
    Inventors: Erkki Ruoslahti, Pirjo Laakkonen
  • Wnt antagonist and methods of treatment and screening
    Patent number: 9579361
    Abstract: The present invention relates to compositions comprising Wnt antagonists and methods of treating Wnt-associated diseases and disorders, such as cancer, inducing differentiation, and reducing the frequency of cancer stem cells, as well as novel methods of screening for such Wnt antagonists. In particular, the invention discloses soluble FZD, SFRP and Ror receptors and their use.
    Type: Grant
    Filed: September 1, 2015
    Date of Patent: February 28, 2017
    Assignee: ONCOMED PHARMACEUTICALS, INC.
    Inventors: Sanjeev H. Satyal, Satyajit Sujit Kumar Mitra, Austin L. Gurney
  • Utility of B-RAF DNA mutation in diagnosis and treatment of cancer
    Patent number: 9567640
    Abstract: The present invention discloses a method of detecting a wild-type or mutant B-RAF gene in a body fluid sample from a subject. Also disclosed are methods of using B-RAF as a biomarker for detecting cancer, predicting the outcome of cancer, and monitoring the treatment of cancer or the status of cancer. Furthermore, the invention discloses methods and compositions for detecting a mutant gene with a peptide nucleic acid clamp capable of hybridizing to a wild-type gene and a locked nucleic acid probe capable of hybridizing to a mutant of the gene.
    Type: Grant
    Filed: May 11, 2012
    Date of Patent: February 14, 2017
    Assignee: JOHN WAYNE CANCER INSTITUTE
    Inventor: Dave S. B. Hoon
  • Utility of B-RAF DNA mutation in diagnosis and treatment of cancer
    Patent number: 9556491
    Abstract: The present invention discloses a method of detecting a wild-type or mutant B-RAF gene in a body fluid sample from a subject. Also disclosed are methods of using B-RAF as a biomarker for detecting cancer, predicting the outcome of cancer, and monitoring the treatment of cancer or the status of cancer. Furthermore, the invention discloses methods and compositions for detecting a mutant gene with a peptide nucleic acid clamp capable of hybridizing to a wild-type gene and a locked nucleic acid probe capable of hybridizing to a mutant of the gene.
    Type: Grant
    Filed: February 26, 2008
    Date of Patent: January 31, 2017
    Assignee: JOHN WAYNE CANCER INSTITUTE
    Inventor: Dave S. B. Hoon
  • Methods for inhibiting angiogenesis using EGFL8 antagonists
    Patent number: 9549971
    Abstract: The present invention provides methods of using EGFL8 antagonists to inhibit vascular development and to treat related disorders.
    Type: Grant
    Filed: January 14, 2009
    Date of Patent: January 24, 2017
    Assignee: GENENTECH, INC.
    Inventors: Weilan Ye, Han Lu
  • Activin-actriia antagonists and uses for treating or preventing breast cancer
    Patent number: 9526759
    Abstract: In certain aspects, the present invention provides compositions and methods for treating or preventing breast cancer in humans.
    Type: Grant
    Filed: February 1, 2008
    Date of Patent: December 27, 2016
    Assignee: Acceleron Pharma Inc.
    Inventors: John Knopf, Jasbir Seehra, Ravindra Kumar
  • Secernin-1 as a marker for cancer
    Patent number: 9518990
    Abstract: Disclosed is a method aiding in the assessment of cancer. It involves the use of the secernin-1 protein (SCRN1) as a universal marker of different cancer types. More specifically disclosed is a method for assessing cancer from a liquid sample derived from an individual by measuring SCRN1 in the sample. Measurement of SCRN1 can, e.g., be used in the early detection of cancer or in the surveillance of patients who undergo surgery.
    Type: Grant
    Filed: October 13, 2011
    Date of Patent: December 13, 2016
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Norbert Wild, Marie-Luise Hagmann, Johann Karl, Julia Riedlinger, Markus Roessler, Michael Tacke
  • Antibodies against Claudin 18.2 useful in cancer diagnosis
    Patent number: 9512232
    Abstract: The invention relates to antibodies directed against an epitope located within the C-terminal portion of CLDN18.2 which are useful, for example, in diagnosing cancer and/or in determining whether cancer cells express CLDN18.2.
    Type: Grant
    Filed: May 6, 2013
    Date of Patent: December 6, 2016
    Assignees: GANYMED PHARMACEUTICALS AG, TRON—Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz gemeinnützige GmbH
    Inventors: Ugur Sahin, Özlem Türeci, Rita Mitnacht-Kraus, Stefan Wöll
  • Melanoma antigen peptide and uses thereof
    Patent number: 9475841
    Abstract: The present invention relates to a melanoma antigen peptide comprising the amino acids sequence selected in the group consisting of SEQ ID NO: 10, SEQ ID NO: 11, SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14 or SEQ ID NO: 15 or a function-conservative variant thereof. Moreover the invention also relates to a melanoma antigen peptide according to the invention for use in the prevention or the treatment of melanoma in patient.
    Type: Grant
    Filed: May 22, 2012
    Date of Patent: October 25, 2016
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITE D'ANGERS
    Inventors: Nathalie Labarriere, Francois Lang, Mathilde Bobinet, Anne Rogel
  • Kit for diagnosing malignant melanoma
    Patent number: 9465030
    Abstract: Provided is a kit for diagnosing at a high reproducibility, said kit being produced by preparing a monoclonal antibody against GPC3 and a monoclonal antibody against SPARC that are superior in quality stability to commercially available and commonly employed antibodies, and using these antibodies.
    Type: Grant
    Filed: June 17, 2013
    Date of Patent: October 11, 2016
    Assignees: NATIONAL CANCER CENTER, LSIP, LLC
    Inventors: Tetsuya Nakatsura, Keigo Saito
  • Humanized monoclonal antibodies and methods of use
    Patent number: 9416169
    Abstract: The present invention comprises a humanized monoclonal antibody that binds to the chemokine receptor CCR4. This antibody is derived from Mab 1567 and recognizes the same epitope. Binding of the invented antibody to CCR4 inhibits ligand-mediated activities and is used to treat symptoms of cancer. Moreover, the antibody is used in combination with vaccines to suppress the activity of regulatory T cells.
    Type: Grant
    Filed: January 14, 2015
    Date of Patent: August 16, 2016
    Assignees: Dana-Farber Cancer Institute, Inc., The Brigham and Women's Hospital
    Inventors: Wayne Marasco, Jianhua Sui, Quan Zhu, Thomas Kupper
  • Kidney-specific tumor vaccine directed against kidney tumor antigen G-250
    Patent number: 9409965
    Abstract: This invention provides an anti-cancer immunogenic agent(s) (e.g. vaccines) that elicit an immune response specifically directed against renal cell cancers expressing a G250 antigenic marker. Preferred immunogenic agents comprise a chimeric molecule comprising a kidney cancer specific antigen (G250) attached to a granulocyte-macrophage colony stimulating factor (GM-CSF). The agents are useful in a wide variety of treatment modalities including, but not limited to protein vaccination, DNA vaccination, and adoptive immunotherapy.
    Type: Grant
    Filed: May 2, 2014
    Date of Patent: August 9, 2016
    Assignee: The Regents of the University of California
    Inventors: Arie Belldegrun, Cho-Lea Tso